SGLT2 inhibitors have moderate effects (risk reduction ~14%) on atherosclerotic major adverse cardiovascular events that seem confined to patients with established atherosclerotic cardiovascular disease or CKD (eGFR < 60 mL/min per 1.73 m2) [11]. This evidence concerns the gene SLC5A2 and chronic kidney disease.